Chapters

Transcript

Video

Can you compare clinical efficacy/equivalency and adverse side effects that have been reported with administration of the anti-TNF biosimilar versus the originator product, infliximab?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Stanley Cohen, MD

Stanley Cohen, MD

Clinical Professor
Department of Internal Medicine
UT Southwestern Medical Center
Co-Director of the Division of Rheumatology
Presbyterian Hospital
Dallas, Texas